Honigman Represents Gemphire Therapeutics Inc. in $30 Million IPO
August 31 2016 - 11:56AM
Business Wire
Honigman Miller Schwartz and Cohn LLP advised Gemphire
Therapeutics Inc. on its $30 million initial public offering. The
company's common stock now trades on The NASDAQ Global Market under
the symbol "GEMP."
Jefferies and RBC Capital Markets acted as joint book-running
managers for the offering. Canaccord Genuity acted as co-lead
manager and Laidlaw & Company (UK) Ltd. and LifeSci Capital
acted as co-managers.
Gemphire is a clinical-stage biopharmaceutical company focused
on developing and commercializing therapies for the treatment of
dyslipidemia, a serious medical condition that increases the risk
of life threatening cardiovascular disease, and nonalcoholic fatty
liver disease.
The Honigman corporate and securities team advising Gemphire
Therapeutics Inc. included Phillip D. Torrence, Meredith Ervine,
Gabrielle Sims, Joscelyn Boucher, Cindy Bott and Stephanie
Swan.
About Honigman Miller Schwartz and Cohn LLP
Honigman Miller Schwartz and Cohn LLP is a business law firm
with nearly 300 attorneys serving clients locally, nationally and
internationally. Headquartered in Detroit, the firm has offices in
Ann Arbor, Bloomfield Hills, Kalamazoo and Lansing, Michigan and in
Chicago, Illinois.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160831006082/en/
LAK Public Relations, Inc.Angel Fahy,
212-575-4545afahy@lakpr.com